• Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 492.11 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$3.04
▼ -0.03 (-0.98%)

This chart shows the closing price for VACC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vaccitech Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VACC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VACC

Analyst Price Target is $18.00
▲ +492.11% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Vaccitech in the last 3 months. The average price target is $18.00, with a high forecast of $20.00 and a low forecast of $16.00. The average price target represents a 492.11% upside from the last price of $3.04.

This chart shows the closing price for VACC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 3 polled investment analysts is to buy stock in Vaccitech.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/4/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/3/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/1/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/30/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/30/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/28/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/27/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/26/2022

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/15/2022Morgan StanleyLower TargetOverweight$19.00 ➝ $16.00Low
8/11/2022HC WainwrightLower TargetBuy$22.00 ➝ $20.00Low
6/23/2022HC WainwrightReiterated RatingBuy$22.00Low
5/12/2022HC WainwrightLower Target$23.00 ➝ $22.00High
1/19/2022HC WainwrightReiterated RatingBuy$23.00Low
12/15/2021HC WainwrightLower TargetBuy$25.00 ➝ $23.00High
11/15/2021HC WainwrightReiterated RatingBuy$24.00Low
10/22/2021William BlairReiterated RatingBuyLow
7/7/2021HC WainwrightReiterated RatingBuy$25.00Low
5/25/2021William BlairInitiated CoverageOutperformHigh
5/25/2021Jefferies Financial GroupInitiated CoverageBuy$28.00High
5/25/2021Morgan StanleyInitiated CoverageOverweight$22.00High
5/24/2021HC WainwrightInitiated CoverageBuy$25.00Medium
(Data available from 9/27/2017 forward)

News Sentiment Rating

1.15 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/1/2022
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/31/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/30/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
5/30/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
6/29/2022
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/29/2022
  • 5 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/28/2022
  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/27/2022

Current Sentiment

  • 4 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Vaccitech logo
Vaccitech plc, a clinical-stage biopharmaceutical company, engages in the discovery and development of novel T cell immunotherapeutics and vaccines for the treatment and prevention of infectious diseases and cancers. The company's therapeutic programs include VTP-300, which is in Phase 1/2a clinical trial for the treatment of chronic hepatitis B infection; VTP-200 that is in Phase 1/2a clinical trial for the treatment of human papilloma virus infection; VTP-850, which is in Phase 1/2 clinical trial for the treatment of prostate cancer; and VTP-600 that is in Phase 1/2a clinical trial for the treatment of non-small cell lung cancer. Its prophylactic programs include VTP-400, which is in preclinical stage for the prevention of herpes zoster or shingles; VTP-500 that has completed Phase 1 clinical trial for the prevention of Middle East respiratory syndrome; and Vaxzevria, a prophylactic vaccine for the prevention of COVID-19 infection. The company was formerly known as Vaccitech Rx Limited and changed its name to Vaccitech plc in March 2021. Vaccitech plc was founded in 2016 and is headquartered in Oxford, the United Kingdom.
Read More

Today's Range

Now: $3.04
Low: $3.04
High: $3.20

50 Day Range

MA: $4.25
Low: $3.04
High: $6.19

52 Week Range

Now: $3.04
Low: $2.76
High: $15.98

Volume

14,523 shs

Average Volume

186,505 shs

Market Capitalization

$113.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vaccitech?

The following sell-side analysts have issued research reports on Vaccitech in the last twelve months: HC Wainwright, Morgan Stanley, and William Blair.
View the latest analyst ratings for VACC.

What is the current price target for Vaccitech?

2 Wall Street analysts have set twelve-month price targets for Vaccitech in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 492.1%. HC Wainwright has the highest price target set, predicting VACC will reach $20.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $16.00 for Vaccitech in the next year.
View the latest price targets for VACC.

What is the current consensus analyst rating for Vaccitech?

Vaccitech currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VACC will outperform the market and that investors should add to their positions of Vaccitech.
View the latest ratings for VACC.

What other companies compete with Vaccitech?

How do I contact Vaccitech's investor relations team?

Vaccitech's physical mailing address is THE SCHRODINGER BUILDING HEATLEY ROAD THE OXFORD SCIENCE PARK, OXFORD X0, OX4 4GE. The company's listed phone number is 44-0-18-6581-8808 and its investor relations email address is [email protected] The official website for Vaccitech is www.vaccitech.co.uk. Learn More about contacing Vaccitech investor relations.